Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Safety and Efficacy Study of Xolair in Peanut Allergy
NCT00086606 · Genentech, Inc. · PHASE2 · terminated · last registry update 2013-01-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Genentech, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-11-26Results posted on the registry: Genentech, Inc., Omalizumab + Placebo (NCT01264939)
- 2013-11-05Phase 3 first posted: Shanghai Zhangjiang Biotechnology Limited Company, Omalizumab + placebo (NCT01976208)
- 2013-10-21Results posted on the registry: University of Utah, omalizumab + Placebo (NCT00123630)
- 2013-10-18Results posted on the registry: Genentech, Inc., Omalizumab + Placebo (NCT01287117)
- 2013-09-02Results posted on the registry: Genentech, Inc., Placebo + Omalizumab (NCT01292473)
- 2013-06-07Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), omalizumab + omalizumab placebo (NCT00377572)
- 2013-03-27Results posted on the registry: Genentech, Inc., Omalizumab + Placebo (NCT00495612)
- 2013-03-04Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Omalizumab (Xolair) + Placebo (NCT01803763)
- 2013-01-18Results posted on the registry: Novartis Pharmaceuticals, omalizumab at a dose of 0.016mg/kg/IU/mL + Placebo (NCT00670930)
- 2012-11-07Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT01723072)
- 2012-10-16Results posted on the registry: University of Iowa, Omalizumab + prednisone (NCT00472030)
- 2012-07-23Also stopped (withdrawn): Novartis Pharmaceuticals, QGE031 + Placebo (NCT01451450)
- 2012-06-08Results posted on the registry: Novartis Pharmaceuticals, omalizumab + Placebo (NCT01007149)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision